三阴性乳腺癌化疗致重度骨髓抑制的危险因素分析及其预测模型的构建 by 黄家良, 夏坤健, 郭伟, 万成鹏, 王琳, 唐娜, 李顶

“…目的探究三阴性乳腺癌（TNBC）化疗致重度骨髓抑制的危险因素，构建TNBC化疗致重度骨髓抑制的预测模型并对其进行验证。方法以2016年9月2日至2021年9月2日在南昌大学第二附属医院接受蒽环类联合环磷酰胺序贯紫杉醇化疗方案的TNBC病人为研究对象，分为重度骨髓抑制组与无/轻度骨髓抑制组。…”
Get full text

The relationship between mutation carriage of BRCA1/2 and clinicopathological characteristics in women with breast cancer – experience from a diagnostic centre in Turkey by Neslihan Duzkale, Onur Can Guler, Suat Kutun, Canan Emiroglu, Serdar Saridemir, Aysun Gokce, Olcay Kandemir, Tugba Taskın Turkmenoglu, Serap Yorubulut, Bahadır Kulah

“…In the study, BRCA1/2 carriage and tumour grade were higher in patients with triple-negative breast cancers (TNBC). The risk of TNBC was 5.560 times higher in BRCA1/2 carriers than in non-carriers. …”
Get full text

Telomerase and mitochondria inhibition promote apoptosis and TET2 and ANMT3a expression in triple negative breast cancer cell lines by Zeinab Mazloumi, Ali Rafat, Khadijeh Dizaji Asl, Mohammad Karimipour, Dariush Shanehbandi, Mehdi Talebi, Majid Montazer, Ali Akbar Movassaghpour, Alireza Dehnad, Raheleh Farahzadi, Hojjatollah Nozad Charoudeh

“…Introduction: High metastasis, resistance to common treatments, and high mortality rate, has made triple-negative breast cancer (TNBC) to be the most invasive type of breast cancer. …”
Get full text

Comparative survival outcomes of neoadjuvant and adjuvant therapy in patients with T1c, node-negative, triple-negative breast cancer: A population-based analysis by Yi-Zi Zheng, Jia-Qi Ying, Ting-Ting Wu, Yong-Hui Su, Ou-Chen Wang

“…Conclusions: In patients with T1cN0M0-stage TNBC, both NAT and AT resulted in equivalent OS and BCSS. …”
Get full text

TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients... by Heather L. McArthur, Sara M. Tolaney, Rebecca Dent, Peter Schmid, Jamil Asselah, Qiang Liu, Jane Lowe Meisel, Naoki Niikura, Yeon Hee Park, Gustavo Werutsky, Giampaolo Bianchini, Jay C. Andersen, Robert Kozarski, Nana Rokutanda, Barbara Pistilli, Sibylle Loibl

“…Background: Despite treatment advances for patients with early-stage triple-negative breast cancer (TNBC) and hormone receptor (HR)-low/human epidermal growth factor receptor 2-negative (HER2−) breast cancer, treatments that improve clinical outcomes while mitigating toxicity are needed. …”
Get full text

Transmembrane Amino Acid Transporters in Shaping the Metabolic Profile of Breast Cancer Cell Lines: The Focus on Molecular Biological Subtype by Elena I. Dyachenko, Lyudmila V. Bel’skaya

“…A distinctive feature of luminal subtypes of breast cancer from TNBC is the ability to perform gluconeogenesis. Breast cancers with a positive expression of the HER2 receptor, in contrast to TNBC and luminal A subtype, have a distinctive active synthesis and consumption of fatty acids. …”
Get full text

Natural products as part of triple negative breast cancer by Yozlem Kobakova, Maria Moneva-Sakelarieva, Spiro Konstantinov, Georgi Momekov, Stefka Achkova Ivanova, Ventseslava Atanasova, Maria Chaneva, Radoslav Tododrov, Nikolay Bashev, Petar Atanasov

“…Triple negative breast cancer (TNBC) continues to be the breast cancer subtype with the highest recurrence and mortality rates. …”
Get full text

Identification of robust RT-qPCR reference genes for studying changes in gene expression in response to hypoxia in breast cancer cell lines by Jodie R. Malcolm, Katherine S. Bridge, Andrew N. Holding, William J. Brackenbury

“…Here we present RPLP1 and RPL27 as optimal RGs for our panel of two Luminal A and two TNBC cell lines cultured in normoxia or hypoxia. …”
Get full text

Unraveling the genetic connections for mitochondrial DNA control region and breast cancer susceptibility by Namra Khalid, Muhammad Umer Khan, Raima Rehman, Shamsa Kanwal, Tazeen Zahid, Muhammad Usman Ghani, Ayesha Iftikhar, Qurban Ali, Muhammad Arshad Javed

“…Triple-Negative Breast Cancer (TNBC) cases are also linked to haplogroup M, showing a statistically significant association with a p-value of 0.002. …”
Get full text

JunD在浸润性乳腺癌分子亚型中的表达及意义 by 代新珍

“…【结果】①与其他分子亚型相比较，JunD在浸润性乳腺癌TNBC亚型中的表达水平明显升高（P<0.05），其他亚型之间两两比较差异无统计学意义（P>0.05）。…”
Get full text

UGCG promotes chemoresistance and breast cancer progression via NF-κB and Wnt/β-catenin pathway activation by Li Long, Lei Wang, Yiran Liang, Fangzhou Ye, Yuhan Jin, Dan Luo, Xiaoyan Li, Yajie Wang, Yaming Li, Dianwen Han, Bing Chen, Wenjing Zhao, Lijuan Wang, Qifeng Yang

“…Background: Taxane-based chemotherapy is the primary treatment for triple-negative breast cancer (TNBC), yet clinical outcomes remain unsatisfactory due to the persistence of chemoresistance. …”
Get full text

Effects of endocrine disrupting chemicals, blood metabolome, and epigenetics on breast cancer risk: A multi-dimensional mendelian randomization study by Ningning Song, Xinquan Xi, Kuan Yang, Chongzhe Pei, Lingzhou Zhao

“…Our results shows that n-butyl paraben (n-BuP) is positively associated with Luminal A, mono-methyl phthalate is negatively associated with Luminal B, and mono-iso-butyl phthalate (MiBP) is positively associated with triple negative breast cancer (TNBC). Mediation analysis reveals that blood metabolites, such as caffeic acid sulfate and the caffeine-to-paraxanthine ratio, mediate the effect of n-BuP on Luminal A, while methylsuccinate mediate the effect of MiBP on TNBC. …”
Get full text

Injectable Autocatalytic Hydrogel Triggers Pyroptosis to Stimulate Anticancer Immune Response for Preventing Postoperative Tumor Recurrence by Zhiping Rao, Yutong Zhu, Zhuang Chen, Yi Luo, Zuo Yang, Weijing Liu, Chaoqiang Qiao, Yuqiong Xia, Peng Yang, Dong‐Man Ye, Zhongliang Wang

“…The results thus suggest great potential for pyroptosis‐based and injectable hydrogel‐aided strategies for preventing the postoperative recurrence of TNBC.…”
Get full text

Functionalized biomimetic nanoparticles loaded with salvianolic acid B for synergistic targeted triple-negative breast cancer treatment by Nuo Cheng, Qianqian Zhou, Zongfang Jia, Yang Mu, Sheng Zhang, Lei Wang, Yunna Chen

“…The therapeutic effect of immune checkpoint inhibitors (ICIs) in triple-negative breast cancer (TNBC) is unsatisfactory. The immune ''cold'' microenvironment caused by tumor-associated fibroblasts (TAFs) has an adverse effect on the antitumor response. …”
Get full text

Genomic characterization and molecular predictive biomarkers for chemotherapy in patients with metastatic triple-negative breast cancer treated in a real-world setting by Erik Olsson, Henrik Lindman, Evangelos Digkas, Viktoria Thurfjell, Haidar Mir Ali, Ute Krüger, Anna-Karin Wennstig, Marie Sundqvist, Antonios Valachis

“…Purpose: We aimed to characterize genomic alterations with potential prognostic or predictive significance in patients with metastatic triple-negative breast cancer (mTNBC) treated with chemotherapy in a real-world setting. …”
Get full text

Network pharmacological analysis and in vitro testing of the rutin effects on triple-negative breast cancer by Chang Cheng, Jia Ruiying, Fang Bin, Miao Yaoyao, Zhang Lili

“…This study aims to assess the potential mechanism of rutin to treat triple-negative breast cancer (TNBC) based on network pharmacology followed by in vitro experiments.…”
Get full text

A preliminary study on the prognostic significance of cysteine-rich EGF ligand domain 2 protein (CRELD2) in patients with triple negative breast cancer by Mehmet Zahid Kocak, Murat Araz, Siddika Findik, Aykut Demirkiran, Mustafa Korkmaz, Melek Karakurt Eryilmaz, Mehmet Artac

“…This study aimed to determine the prognostic value of CRELD2 status on survival outcomes in triple-negative breast cancer (TNBC). Seventy patients were included in the study. …”
Get full text

“Subtype-precise” therapy leads diagnostic and therapeutic innovations: a new pattern for precision treatment of breast cancer by ZHANG Siwei, MA Ding, JIANG Yizhou, SHAO Zhimin

“…Clinically, breast cancer is classified into luminal, HER2-positive, and triple-negative breast cancer (TNBC) based on the expression of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2), with corresponding treatments including endocrine therapy, anti-HER2 targeted therapy, and chemotherapy. …”
Get full text

Blood Genome-Wide Transcriptional Profiles of HER2 Negative Breast Cancers Patients by Ovidiu Balacescu, Loredana Balacescu, Oana Virtic, Simona Visan, Claudia Gherman, Flaviu Drigla, Laura Pop, Gabriela Bolba-Morar, Carmen Lisencu, Bogdan Fetica, Oana Tudoran, Ioana Berindan-Neagoe

“…Our data showed the implication of immune signaling in both breast cancer subtypes with an enrichment of these processes in the blood of TNBC patients. We observed a significant alteration of “chemokine signaling,” “IL-8 signaling,” and “communication between innate and adaptive immune cells” pathways in the blood of TNBC patients correlated with an increased inflammation and necrosis in their primary tumors. …”
Get full text

Neoadjuvant apatinib addition to sintilimab and carboplatin-taxane based chemotherapy in patients with early triple-negative breast cancer: the phase 2 NeoSAC trial by Guoshuang Shen, Zhilin Liu, Miaozhou Wang, Yi Zhao, Xinlan Liu, Yujin Hou, Wenbiao Ma, Jingqi Han, Xiaofeng Zhou, Dengfeng Ren, Fuxing Zhao, Zitao Li, Shifen Huang, Yongzhi Chen, Yingjian He, Yan Liu, Zijun Zhu, Yongxin Li, Jinming Li, Mengting Da, Hongnan Mo, Feng Du, Liang Cui, Jing Bai, Zhen Liu, Fei Ma, Jiuda Zhao

“…Abstract We aimed to evaluate the efficacy and safety of adding apatinib, to sintilimab and chemotherapy in the neoadjuvant treatment of early triple-negative breast cancer (TNBC). In the phase 2 NeoSAC trial, patients with early TNBC received six cycles of apatinib, sintilimab, nab-paclitaxel, and carboplatin followed by surgery. …”
Get full text